Insulet Corporation revised earnings guidance for the year ending December 31, 2024. For the year ending December 31, 2024, the company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
192 USD | +0.32% | +5.86% | -11.49% |
Jun. 06 | Transcript : Insulet Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 09:00 AM | |
May. 30 | Redburn Atlantic Initiates Insulet With Buy Rating, $235 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.49% | 13.41B | |
-2.34% | 187B | |
+0.92% | 110B | |
-1.77% | 69.54B | |
+14.21% | 46.37B | |
-6.06% | 46.05B | |
+8.71% | 42.54B | |
+19.03% | 30.72B | |
+18.93% | 25.62B | |
-7.25% | 23.32B |
- Stock Market
- Equities
- PODD Stock
- News Insulet Corporation
- Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024